keyword
MENU ▼
Read by QxMD icon Read
search

Ginkgo evaluation of memory gem

keyword
https://www.readbyqxmd.com/read/26313420/associations-between-mild-cognitive-impairment-and-hospitalization-and-readmission
#1
MULTICENTER STUDY
Kathryn E Callahan, James F Lovato, Michael E Miller, Doug Easterling, Beth Snitz, Jeff D Williamson
OBJECTIVES: To determine whether older adults with mild cognitive impairment (MCI), a condition not previously explored as a risk factor, have more hospitalizations and 30-day readmissions than those with normal cognition. DESIGN: Post hoc analysis of prospectively gathered data on incident hospitalization and readmission from the Ginkgo Evaluation of Memory Study (GEMS), a randomized, double-blind, placebo-controlled trial designed to assess the effect of Ginkgo biloba on incidence of dementia...
September 2015: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/23911756/antihypertensive-drugs-decrease-risk-of-alzheimer-disease-ginkgo-evaluation-of-memory-study
#2
RANDOMIZED CONTROLLED TRIAL
Sevil Yasar, Jin Xia, Wenliang Yao, Curt D Furberg, Qian-Li Xue, Carla I Mercado, Annette L Fitzpatrick, Linda P Fried, Claudia H Kawas, Kaycee M Sink, Jeff D Williamson, Steven T DeKosky, Michelle C Carlson
OBJECTIVES: The aim of this study was to determine whether use of diuretics, angiotensin-1 receptor blockers (ARB), angiotensin-converting enzyme inhibitors (ACE-I), calcium channel blockers (CCB), or β-blockers (BB) was associated with a reduced risk of Alzheimer disease (AD) dementia in participants with normal cognition or mild cognitive impairment (MCI). METHODS: Secondary longitudinal data analysis of the Ginkgo Evaluation of Memory Study in older adults at least 75 years of age with normal cognition (n = 1,928) or MCI (n = 320) over a median 6...
September 3, 2013: Neurology
https://www.readbyqxmd.com/read/23516317/cognitive-trajectories-associated-with-%C3%AE-amyloid-deposition-in-the-oldest-old-without-dementia
#3
MULTICENTER STUDY
Beth E Snitz, Lisa A Weissfeld, Oscar L Lopez, Lewis H Kuller, Judith Saxton, Dilrukshika M Singhabahu, William E Klunk, Chester A Mathis, Julie C Price, Diane G Ives, Ann D Cohen, Eric McDade, Steven T Dekosky
OBJECTIVE: To determine whether a high prevalence (55%) of Aβ deposition in a cohort of individuals remaining dementia-free into their 9th and 10th decades is associated with cognitive decline prior to imaging. METHODS: A total of 194 participants (mean age 85.5 years, range 82-95) who completed the Ginkgo Evaluation of Memory Study (GEMS) and remained dementia-free subsequently completed Pittsburgh compound B-PET imaging. We examined cross-sectional associations between Aβ status and performance on a broad neuropsychological test battery completed at GEMS entry 7-9 years prior to neuroimaging...
April 9, 2013: Neurology
https://www.readbyqxmd.com/read/22465175/diuretic-use-is-associated-with-better-learning-and-memory-in-older-adults-in-the-ginkgo-evaluation-of-memory-study
#4
RANDOMIZED CONTROLLED TRIAL
Sevil Yasar, Fu-Mei Lin, Linda P Fried, Claudia H Kawas, Kaycee M Sink, Steven T DeKosky, Michelle C Carlson
BACKGROUND: To investigate the association between diuretics, angiotensin-converting enzyme inhibitors (ACE-I), angiotensin II receptor blockers (AT2RB), and cognitive function. METHODS: This post hoc analysis of the randomized controlled Ginkgo Evaluation of Memory Study trial focuses on 3069 nondemented community-dwelling participants aged >75 years. At baseline visit, detailed information about medication use was collected and five cognitive domains were assessed...
May 2012: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://www.readbyqxmd.com/read/20582906/ginkgo-biloba-and-risk-of-cancer-secondary-analysis-of-the-ginkgo-evaluation-of-memory-gem-study
#5
RANDOMIZED CONTROLLED TRIAL
Mary L Biggs, Barbara C Sorkin, Richard L Nahin, Lewis H Kuller, Annette L Fitzpatrick
PURPOSE: Evidence from in vitro and in vivo studies suggests that Ginkgo biloba has cancer chemopreventive properties, but epidemiological evidence is sparse. We analyzed cancer as a secondary endpoint in the Ginkgo Evaluation of Memory (GEM) Study, the largest randomized, double-blind, placebo-controlled clinical trial of Ginkgo supplementation to date. METHODS: A total of 3069 GEM participants 75+ years of age were randomized to twice-daily doses of either 120 mg Ginkgo extract (EGb 761) or placebo and followed for a median 6...
July 2010: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/20168306/effect-of-ginkgo-biloba-on-blood-pressure-and-incidence-of-hypertension-in-elderly-men-and-women
#6
RANDOMIZED CONTROLLED TRIAL
Tina E Brinkley, James F Lovato, Alice M Arnold, Curt D Furberg, Lewis H Kuller, Gregory L Burke, Richard L Nahin, Oscar L Lopez, Sevil Yasar, Jeff D Williamson
BACKGROUND: Accumulating evidence suggests that Ginkgo biloba is cardioprotective, in part, through its vasodilatory and antihypertensive properties. However, definitive data on its blood pressure (BP)-lowering effects in humans is lacking. METHODS: We determined the effects of G. biloba extract (240 mg/day) on BP and incident hypertension in 3,069 participants (mean age, 79 years; 46% female; 96% white) from the Ginkgo Evaluation of Memory (GEM) study. We also examined whether the treatment effects are modified by baseline hypertension status...
May 2010: American Journal of Hypertension
https://www.readbyqxmd.com/read/20040554/ginkgo-biloba-for-preventing-cognitive-decline-in-older-adults-a-randomized-trial
#7
RANDOMIZED CONTROLLED TRIAL
Beth E Snitz, Ellen S O'Meara, Michelle C Carlson, Alice M Arnold, Diane G Ives, Stephen R Rapp, Judith Saxton, Oscar L Lopez, Leslie O Dunn, Kaycee M Sink, Steven T DeKosky
CONTEXT: The herbal product Ginkgo biloba is taken frequently with the intention of improving cognitive health in aging. However, evidence from adequately powered clinical trials is lacking regarding its effect on long-term cognitive functioning. OBJECTIVE: To determine whether G. biloba slows the rates of global or domain-specific cognitive decline in older adults. DESIGN, SETTING, AND PARTICIPANTS: The Ginkgo Evaluation of Memory (GEM) study, a randomized, double-blind, placebo-controlled clinical trial of 3069 community-dwelling participants aged 72 to 96 years, conducted in 6 academic medical centers in the United States between 2000 and 2008, with a median follow-up of 6...
December 23, 2009: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/19515113/concomitant-use-of-prescription-drugs-and-dietary-supplements-in-ambulatory-elderly-people
#8
Richard L Nahin, Monica Pecha, Diana B Welmerink, Kaycee Sink, Steven T DeKosky, Annette L Fitzpatrick
OBJECTIVES: To analyze baseline data on concomitant use of prescription drugs and dietary supplements in elderly people from the Ginkgo Evaluation of Memory (GEM) Study, in which information was collected on all drugs and supplements used by participant. DESIGN: Cross-sectional correlation analysis. SETTING: GEM Study sites in California, Maryland, North Carolina, and Pennsylvania. PARTICIPANTS: Three thousand seventy ambulatory individuals aged 75 and older enrolled between September 2000 and June 2002...
July 2009: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/19347684/identifying-mild-cognitive-impairment-at-baseline-in-the-ginkgo-evaluation-of-memory-gem-study
#9
Beth E Snitz, Judith Saxton, Oscar L Lopez, Diane G Ives, Leslie O Dunn, Stephen R Rapp, Michelle C Carlson, Annette L Fitzpatrick, Steven T Dekosky
OBJECTIVES: To identify, characterize and compare the frequency of mild cognitive impairment (MCI) subtypes at baseline in a large, late-life cohort (n = 3063) recruited into a dementia prevention trial. METHOD: A retrospective, data-algorithmic approach was used to classify participants as cognitively normal or MCI with corresponding subtype (e.g. amnestic vs. non-amnestic, single domain vs. multiple domain) based on a comprehensive battery of neuropsychological test scores, with and without Clinical Dementia Rating (CDR) global score included in the algorithm...
March 2009: Aging & Mental Health
https://www.readbyqxmd.com/read/19279031/functional-and-cognitive-criteria-produce-different-rates-of-mild-cognitive-impairment-and-conversion-to-dementia
#10
MULTICENTER STUDY
J Saxton, B E Snitz, O L Lopez, D G Ives, L O Dunn, A Fitzpatrick, M C Carlson, S T Dekosky
OBJECTIVE: To compare rates of mild cognitive impairment (MCI) and rates of progression to dementia using different MCI diagnostic systems. METHODS: MCI was investigated at baseline in 3063 community dwelling non-demented elderly in the Ginkgo Evaluation of Memory (GEM) study who were evaluated every 6 months to identify the presence of dementia. Overall MCI frequency was determined using (1) a Clinical Dementia Rating (CDR) score of 0.5 and (2) neuropsychological (NP) criteria, defined by impairment on standard cognitive tests...
July 2009: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/19017911/ginkgo-biloba-for-prevention-of-dementia-a-randomized-controlled-trial
#11
RANDOMIZED CONTROLLED TRIAL
Steven T DeKosky, Jeff D Williamson, Annette L Fitzpatrick, Richard A Kronmal, Diane G Ives, Judith A Saxton, Oscar L Lopez, Gregory Burke, Michelle C Carlson, Linda P Fried, Lewis H Kuller, John A Robbins, Russell P Tracy, Nancy F Woolard, Leslie Dunn, Beth E Snitz, Richard L Nahin, Curt D Furberg
CONTEXT: Ginkgo biloba is widely used for its potential effects on memory and cognition. To date, adequately powered clinical trials testing the effect of G. biloba on dementia incidence are lacking. OBJECTIVE: To determine effectiveness of G. biloba vs placebo in reducing the incidence of all-cause dementia and Alzheimer disease (AD) in elderly individuals with normal cognition and those with mild cognitive impairment (MCI). DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled clinical trial conducted in 5 academic medical centers in the United States between 2000 and 2008 with a median follow-up of 6...
November 19, 2008: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/18165850/comparison-of-the-design-differences-between-the-ginkgo-evaluation-of-memory-study-and-the-guidage-study
#12
COMPARATIVE STUDY
J D Williamson, B Vellas, C Furberg, R Nahin, S T Dekosky
The epidemic of late life dementia, prominence of use of alternative medications and supplements, and initiation of efforts to determine how to prevent dementia have led to efforts to conduct studies aimed at prevention of dementia. The GEM (Ginkgo Evaluation of Memory) and GuidAge studies are ongoing randomized double-blind, placebo-controlled trials of Ginkgo biloba, administered in a dose of 120 mg twice per day as EGb761, to test whether Ginkgo biloba is effective in the prevention of dementia (and especially Alzheimer's disease) in normal elderly or those early cognitive impairment...
January 2008: Journal of Nutrition, Health & Aging
https://www.readbyqxmd.com/read/18000144/associations-of-gait-speed-and-other-measures-of-physical-function-with-cognition-in-a-healthy-cohort-of-elderly-persons
#13
Annette L Fitzpatrick, Catherine K Buchanan, Richard L Nahin, Steven T Dekosky, Hal H Atkinson, Michelle C Carlson, Jeff D Williamson
BACKGROUND: Recent evidence suggests that physical decline and slower gait may be associated with early signs of dementia, but more information on healthy older adults is needed. METHODS: We determined associations between cognitive function, gait speed, and self-reported measures of physical function in 3035 healthy mobile participants of the Ginkgo Evaluation of Memory Study evaluated in 2000-2001. Gait speed was measured over a 15-foot course with participants walking at both their usual and rapid pace...
November 2007: Journals of Gerontology. Series A, Biological Sciences and Medical Sciences
https://www.readbyqxmd.com/read/17101930/primary-prevention-trials-in-alzheimer-disease
#14
REVIEW
Robert C Green, Steven T DeKosky
Many new treatments under development for Alzheimer disease (AD) will be disease-modifying rather than symptomatic. Clinical evaluation of these treatments will require primary and secondary prevention trials. We describe some of the methodologic challenges in designing primary prevention trials for AD and illustrate these with examples from the ADAPT (Alzheimer Disease Anti-Inflammatory Prevention Trial) Study and GEM (Ginkgo in Evaluation of Memory) Study. Primary prevention trials for AD present many design challenges...
November 14, 2006: Neurology
https://www.readbyqxmd.com/read/17087700/use-of-herbal-medicine-and-other-dietary-supplements-in-community-dwelling-older-people-baseline-data-from-the-ginkgo-evaluation-of-memory-study
#15
MULTICENTER STUDY
Richard L Nahin, Annette L Fitzpatrick, Jeff D Williamson, Gregory L Burke, Steven T Dekosky, Curt Furberg
OBJECTIVES: To analyze baseline data from the Ginkgo Evaluation of Memory (GEM) study, in which information was collected on the use of all dietary supplements. DESIGN: Cross-sectional regression analysis. SETTING: GEM study sites in California, Maryland, North Carolina, and Pennsylvania. PARTICIPANTS: The GEM study enrolled 3,072 ambulatory individuals aged 75 and older between September 2000 and June 2002. MEASUREMENTS: Self-reported use of dietary supplements and use identified through bottles brought to the clinic...
November 2006: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/16949348/recruitment-of-the-elderly-into-a-pharmacologic-prevention-trial-the-ginkgo-evaluation-of-memory-study-experience
#16
RANDOMIZED CONTROLLED TRIAL
Annette L Fitzpatrick, Linda P Fried, Jeff Williamson, Patricia Crowley, Delilah Posey, Linly Kwong, Janet Bonk, Roberta Moyer, Joyce Chabot, Lara Kidoguchi, Curt D Furberg, Steven T DeKosky
The difficulty involved in recruiting healthy older adults into clinical trials, especially those involving pharmacologic agents, is an important issue in research. The Ginkgo Evaluation of Memory (GEM) Study, a double-blind, placebo-controlled randomized clinical trial evaluating Ginkgo biloba to prevent dementia, successfully recruited 3072 participants age 75 years and older at four U.S. sites from September 2000 through June 2002. Using targeted mailing lists, an estimated 243,400 study brochures were mailed out to potential participants...
December 2006: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/16627007/the-ginkgo-evaluation-of-memory-gem-study-design-and-baseline-data-of-a-randomized-trial-of-ginkgo-biloba-extract-in-prevention-of-dementia
#17
Steven T DeKosky, Annette Fitzpatrick, Diane G Ives, Judith Saxton, Jeff Williamson, Oscar L Lopez, Gregory Burke, Linda Fried, Lewis H Kuller, John Robbins, Russell Tracy, Nancy Woolard, Leslie Dunn, Richard Kronmal, Richard Nahin, Curt Furberg
The epidemic of late life dementia, prominence of use of alternative medications and supplements, and initiation of efforts to determine how to prevent dementia have led to efforts to conduct studies aimed at prevention of dementia. The GEM (Ginkgo Evaluation of Memory) study was initially designed as a 5-year, randomized double-blind, placebo-controlled trial of Ginkgo biloba, administered in a dose of 120 mg twice per day as EGb761, in the prevention of dementia (and especially Alzheimer's disease) in normal elderly or those with mild cognitive impairment...
June 2006: Contemporary Clinical Trials
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"